Two independent cardioprotective interventions, Na + /H +
Introduction
The no-reflow phenomenon after temporary coronary artery occlusion, characterized by distinct zones of compromised tissue perfusion and microvascular damage within the previously ischemic tissue (1, 23, 24) , is closely correlated with infarct size after different durations of ischemia and reperfusion (35). Recent investigations on microvascular reperfusion injury in a rabbit model of 30 minutes of coronary artery occlusion followed by reperfusion demonstrated a dramatic expansion of anatomic no-reflow during the first two hours of reperfusion, finally encompassing about 80% of the necrotic myocardium with a close spatial accordance (36). Hence, any significant infarct size reducing intervention may concomitantly require reduction of microvascular injury.
Out of various cardioprotective interventions, Na
+ /H + -exchange inhibition (2, 3, 38) and ischemic preconditioning (PC) (32) represent two of the most powerful and reproducible infarct size reducing measures in experimental models of coronary occlusion and reperfusion, that exhibit their actions via different and independent pathways.
In addition to cardioprotective effects in vivo, experiments in other models, including cardiomyocytes and endothelial cells in isolated cell preparations, demonstrated that both Na + /H + -exchange inhibition (2, 16, 17, 14, 42 ) and preconditioning-like interventions (4, 19, 43) render the cardiomyocyte as well as the vasculature more resistant toward ischemic or hypoxic damage. Furthermore, Na + /H + -exchange inhibition in the canine model of ischemia/reperfusion exhibits modulatory effects on neutrophils (11), which might be involved in microvascular reperfusion injury, and may attenuate endothelial dysfunction (14).
Thus, if microvascular and myocardial damage in vivo were two different and independent entities, one would expect that different and independent measures of cardioprotection result in differential microvascular and myocardial protection. However, if microvascular and myocardial salvage during reperfusion were causally linked, one would expect that neither intervention could uncouple no-reflow from myocardial necrosis.
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Therefore, the present study was designed to investigate the ability of cariporide (Car), a specific inhibitor of the Na + /H + -exchanger isoform 1 (39), and ischemic preconditioning to reduce infarct size and anatomic no-reflow in an in-vivo model of ischemia/reperfusion, and to elucidate whether microvascular salvage and myocardial salvage are affected independently by these interventions.
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Methods
The experiments were conducted in accordance with the national and institutional
Guide for the Care and Use of Laboratory Animals.
Animal Preparation
New Zealand White male rabbits (2.0-3.2 kg) were anesthetized by intramuscular ketamine (400 mg) and xylazine (200 mg). After tracheotomy, and initiation of ventilation (Harvard Apparatus Respirator, Model 665, South Natick, Mass), using room air enriched with 1.5 l/min oxygen, fluid-filled catheters were inserted into the right jugular vein and carotid artery for additional anesthesia (pentobarbital, as needed) and continuous monitoring of arterial blood pressure.
After left lateral thoracotomy in the 4 th intercostal space and pericardial incision, a major branch of the circumflex coronary artery was encircled by a suture (4-0 silk suture, Ethicon Inc, Sommerville, NJ). The two ends of the suture were threaded through a piece of plastic tubing, forming a snare, which could be tightened to achieve coronary artery occlusion. A fluid-filled catheter was inserted into the left atrial appendage and fixed. Body temperature, monitored as rectal temperature, was maintained by a heating pad.
Hemodynamics
Heart rate, and systolic and diastolic blood pressure were measured and averaged over three consecutive cardiac cycles for each sample period.
Assessment of ischemic risk area, area of no-reflow (ANR) and infarct size
At the end of the protocol, 1 ml/kg 4% thioflavin S (SIGMA chemical Co., St Louis, MO, dissolved in 0.9% saline, then centrifuged (1,500 rpm) for five minutes) was injected into the left atrium. Thioflavin S is a vital fluorescent stain for endothelium. After 6 approximately one minute, the coronary artery was re-occluded and 4 ml 50% Uniperse blue (Ciba Geigy, Hawthorne, NY) was injected into the left atrium to measure the ischemic risk area. The rabbit was euthanized by an intravenous overdose of xylazine (100 mg) followed by 12 mEq potassium chloride (intraatrial). The heart was removed, and the left ventricle was sliced into 6 -7 transverse sections, which were photographed under water, re-photographed under ultraviolet light in a dark room (365 nm wave length, Spectroline Model ENF 280 C, Spectronics Co., Westbury, NY) using a Y48 barrier filter (Minolta), and again photographed after incubation in 1% triphenyltetrazolium chloride (TTC, 37° C, for approximately 15 minutes). TTC stains viable myocardium red; necrotic tissue appears pale yellow. The nonfluorescence area within the risk area was defined as the area of no-reflow (ANR), while fluorescence in the rest of the heart appeared to be homogeneous. The contour of each slice, the risk area (RA; not stained by the blue dye), the ANR, and infarct size (IS), not stained by TTC, were traced manually from projected slides. After computerized planimetry, the percentage of the areas was multiplied by the weight of the slice. The RA was expressed as a percentage of the weight of the left ventricle, the ANR and IS as a percentage of the weight of the risk area.
Regional myocardial blood flow (RMBF)
RMBF was measured by intraatrial injection of approximately 500,000 microspheres per measurement, labeled with 141 Cerium or 103 Ruthenium, at 30 minutes and 180 minutes of reperfusion. Simultaneously, a reference blood sample was withdrawn through the arterial catheter at a rate of 2.06 ml/min. The hearts were cut into samples stained by the blue dye (non-ischemic tissue) and not stained by the dye (tissue at risk). Tissue and blood sample radioactivity was counted in a multi-channel pulse-height analyzer (model ND62, Nuclear Data Schaumburg, IL). RMBF was calculated after correction for background and crossover as the ratio of counts in the tissue and the reference blood sample multiplied by the reference flow rate and divided by the weight of the tissue sample.
Protocol 1. Cariporide prior to occlusion versus ischemic preconditioning
In protocol 1, animals were randomly assigned to one of three groups (control, cariporide prior to occlusion, preconditioning, n = 12, each). Approximately 15 minutes after surgery, the animals in the cariporide group received a bolus of 300 µg/kg cariporide intravenously (1 g/l solution in distilled water); the other animals received 300 µl/kg distilled water, intravenously. In the preconditioning group, the coronary artery was occluded for 5 minutes, followed by 10 minutes of reperfusion. After that, or 15 minutes after injection of the bolus in the control and cariporide group, the coronary artery was occluded for 30 minutes, followed by reperfusion for 180 minutes. Regional myocardial blood flow was measured at 30 minutes of reperfusion and at the end of the protocol, before thioflavin S was injected.
Protocol 2. Cariporide at reperfusion
Approximately 15 minutes after surgery, the coronary artery was occluded for 30 minutes. Thereafter, the animals were randomized to either control, or cariporide treatment (n=8, each). Control animals received an intravenous bolus of 300 µl/kg distilled water five minutes prior to reflow (25 minute occlusion). In the treatment group, 300 µg/kg cariporide was administered at the same time. Again, measurement of RMBF was performed at 30 minutes of reperfusion and at the end of the protocol.
Statistical analysis
Animals showing a risk area of less than 20% of the left ventricle, as well as not- 
Results
Exclusions
In protocol 1, four animals, that died during the experimental procedure (2 Car-group, 1 PC-group, 1 control animal), and two animals with a risk area of less than 20% (1 Car, 1 PC), were excluded and replaced. Presented data are based on 12 animals in each group. In protocol 2, four animals died (2 controls, and 2 before randomization), and one heart showed a risk area of less than 20% (control). In protocol 2, presented data are based on eight animals in both groups.
Protocol 1: Cariporide prior to occlusion, and ischemic preconditioning versus control
Hemodynamics (table 1)
Coronary occlusion resulted in decreased systolic and diastolic blood pressure, accompanied by an increase in heart rate in all groups. During reperfusion, blood pressure tended to further decrease, along with additional increase in heart rate. Statistical analysis revealed a time-related effect for all parameters (p<0.01) without differences between groups.
For systolic blood pressure, an interaction effect was found, due to a significant decrease of systolic blood pressure from baseline to pre-occlusion in the preconditioning group (p<0.05).
During occlusion blood pressure was similar among the groups. 
Risk area, infarct size, and area of no reflow (table 2, figure 1)
The RA in the three groups did not significantly differ from each other (table 2) . Both interventions significantly reduced infarct size in comparison to control (p<0.01), cariporide by 62% (p<0.01), and ischemic preconditioning by 40% (p<0.01). The higher degree of infarct size reduction by cariporide did not reach statistical significance, compared with preconditioning. Concomitantly, the area of no-reflow was significantly reduced by 53% in the cariporide group, and by 34% for the preconditioning animals, without significant differences between the two treatments (figure 1, left).
Regional myocardial blood flow (figure 2)
Regional myocardial blood flow in the risk area declined in each group between 30 minutes of reperfusion and 180 minutes of reperfusion, while blood flow in the non-ischemic tissue remained constant, or even slightly increased (figure 2, left). RMBF in the RA declined from 79±6% to 26±2% of non-ischemic blood flow between 30 and 180 minutes of reperfusion in the control group. At both time points during reperfusion, this percentage was increased in the two treatment groups (Car: 110±12% to 49±7%, PC: 109±8% to 38±6%, group effect: p<0.05 either treatment versus control). The decline over time in either treatment group was proportional to the decline in the control group (time-related effect: p<0.01, no interaction).
Relationship between infarct size, area of no-reflow, and regional myocardial blood flow
In each group, the size of the area of no-reflow and infarct size were significantly correlated (r=0.92-0.95, figure 1, left), and their spatial distribution showed a high accordance. Notably, the regression lines between infarct size and area of no-reflow were very similar in the three groups, indicating that the reduction of no-reflow with both interventions was always coupled with a parallel infarct size reduction. Infarct size and RMBF in the risk area, as a percent of non-ischemic flow, at 30 and 180 minutes of reperfusion showed an inverse correlation in each group, but probably because of the relatively high variability of these data, especially at 30 minutes of reperfusion, these correlations did not reach statistical significance in every group (figure 3, left). The distribution of the individual data points and the regression lines again suggested that the increased regional myocardial blood flow in the cariporide and preconditioning group is mainly the result of infarct size reduction in these groups.
Protocol 2: Cariporide at reperfusion versus control
Hemodynamics (table 3)
Hemodynamics and temperature in protocol 2 followed a similar pattern during occlusion and reperfusion as in protocol 1. Heart rate and temperature in the control group were slightly, but significantly higher than in the cariporide group without interaction effect.
Blood pressure data were comparable between the two groups.
Risk area, infarct size, and area of no-reflow (table 4, figure 1)
The risk area in the cariporide group did not significantly differ from control (table 4) Cariporide at reperfusion did not reduce infarct size as a percentage of the RA, indeed average infarct size was somewhat higher in comparison with control (p<0.31 for two-tailed t-test).
Concomitantly, the area of no-reflow was slightly larger in the cariporide group (p<0.27, for two tailed t-test).
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Regional myocardial blood flow (figure 2)
In both groups, RMBF in the risk area declined over time, similar to the control group in protocol 1. RMBF within the RA decreased from 79±12% to 35±6% of non-ischemic flow in the control group, and 84±8% to 28±5% in the cariporide group. Two-way ANOVA revealed a significant time-related effect (p<0.01) without significant differences between the two groups or interaction effects (figure 2, right).
Relationship between infarct size, area of no-reflow, and regional myocardial blood flow
The area of no-reflow and infarct size in these two groups were again significantly 
Discussion
This study confirms the powerful infarct size reducing potential of ischemic preconditioning and Na + /H + exchange inhibition, when commenced prior to ischemia, in the rabbit model of 30 minutes coronary occlusion, followed by reperfusion (13 It is unlikely that our study did not show a significant difference because of insufficient power of the statistical test, as infarct size was even somewhat higher in the cariporide group. The reasons for these contradictory results remain unexplained.
In the present study, infarct size reduction, as a result of ischemic preconditioning and treatment with cariporide prior to occlusion, was accompanied by a pronounced reduction of anatomic no-reflow. Although the major amount of no-reflow in this model depends on reperfusion injury and develops during the first two hours of reperfusion (36), cariporide given shortly before reperfusion, which failed to reduce infarct size in this study, did also not reduce anatomic no-reflow. Indeed, linear regression analysis for all these groups revealed a nearly identical relationship between infarct size and anatomic no-reflow.
Na + /H + exchange inhibition and ischemic preconditioning -two different and independent cardioprotective interventions
Two of the most powerful and reproducible cardioprotective interventions in experimental models of coronary occlusion and reperfusion were chosen in this study (13).
Different and independent mechanisms are believed to confer the infarct size reducing effects 
Is their a causal link between microvascular and myocardial salvage?
In theory, there are two explanations for the nearly identical relationships between infarct size and perfusion defects with different interventions: a parallel independent protective effect of the two interventions on the microvasculature and the cardiomyoctes, or a causal link between perfusion defects and necrosis. If microvascular and myocardial protection by the two interventions were independent entities and not causally linked, one would have to assume that the apparently proportional amount of microvascular and myocardial protection conferred by Na + /H + -exchange inhibition and ischemic preconditioning were just coincidental. As neither of the two independent cardioprotective interventions, investigated in this study, uncoupled the relationship between infarct size and no-reflow, a causal connection between microvascular and myocardial damage appears to be the more likely explanation.
In a recent study, we analyzed the relationship between no-reflow and infarct size after different durations of myocardial ischemia and reperfusion: After two hours of reperfusion, infarct size was the main determining factor for no-reflow, notwithstanding the duration of ischemia (35). If myocardial and microvascular damage were not causally connected, one would think that lengthening the duration of ischemia would lead to different increases in the necrotic zones and worsening of no-reflow. Since this was not the case, the more likely and simpler explanation would be a causal connection between necrosis and no-reflow.
Microvascular and myocardial damage in reperfused infarcts
Although a causal connection between microvascular and myocardial damage is a reasonable explanation for our results in this model of reperfused myocardial infarction without relevant collateral flow (36), the findings do not identify the factor connecting them. 
Summary and Conclusions
In this study, ischemic preconditioning and Na + /H + exchange inhibition, when commenced prior to ischemia, exhibited pronounced microvascular and myocardial 
